A mathematical model to estimate global hepatitis B disease burden and vaccination impact

International Journal of Epidemiology

Volumn 34, Issue 6, 2005, Pages 1329-1339

  Goldstein, Susan T ^a   Zhou, Fangjun ^b   Hadler, Stephen C ^b   Bell, Beth P ^a   Mast, Eric E ^a   Margolis, Harold S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

Chronic hepatitis B; Chronic liver disease; Cirrhosis; Hepatitis B; Hepatitis B vaccine; Hepatocellular carcinoma

Indexed keywords

HEPATITIS B VACCINE;

HEALTH AND DISEASE;

ACUTE HEPATITIS; ARTICLE; DISEASE COURSE; DRUG EFFICACY; HEPATITIS B; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; PERINATAL INFECTION; PRIORITY JOURNAL; SURVIVAL; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; MODELS, BIOLOGICAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VACCINATION; WORLD HEALTH;

HEPATITIS B VIRUS;

EID: 29244437488     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyi206     Document Type: Article

References (68)

1. Beutels P. Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000). Health Econ 2001;10:751-74.
2. World Health Assembly. Resolution WHA 45.17. Immunization and vaccine quality. Geneva: World Health Assembly, 1992.
3. Centers for Disease Control and Prevention. Global progress toward universal childhood hepatitis B vaccination. MMWR Morb Mortal Wkly Rep 2003;52:868-70.
4. Hyams K. Risks of chronicity following acute hepatitis B virus infection: A review. Clin Infect Dis 1995;20:992-1000.
5. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Royal Soc London 1993;253:107-201.
6. World Health Report 2003: Shaping the Future. Geneva, Switzerland: World Health Organization 2003.
7. Centers for Disease Control and Prevention. Cause-specific adult mortality: Evidence from community-based surveillance - selected sites, Tanzania, 1992-1998. MMWR Morb Mortal Wkly Rep 2000;49: 416-19.
8. Okada K, Kamiyama I, InomataM, Imai M, Miyakawa Y. E antigen and anti-E in the serum of asymptomatic carrier mother as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976;294:746-49.
9. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94-98.
10. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: Correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979;3:237-41.
11. Beasley RP, Hwang LY, Stevens CE et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3:135-41.
12. Xu ZY, Liu CB, Francis DP et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: Preliminary report of a randomized double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-18.
13. Farmer K, Gunn T, Woodfield DG. Passive immunoprophylaxis of hepatitis B virus infection in newborn infants. N Z Med J 1985;98: 851-53.
14. Stevens CE, Beasley P, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-74.
15. McMahon BJ, Alward W, Hall D et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
16. Beasley RP, Hwang LY, Lin CC et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982;146: 198-204.
17. Beasley RP, Hwang LY, Lin CC, Ko YC, Twu SJ. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol 1983;117:213-22.
18. Scott RM, Schneider RJ, Snitbhan R, Karwacki JJ Jr. Factors relating to transmission of viral hepatitis in a United States military population stationed in Thailand. Am J Epidemiol 1981;113:520-28.
19. Lee WM. Medical Progress: Hepatitis B Virus Infection. N Engl J Med 1997;337:1733-45.
20. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. JAMA 1995;274:1201-08.
21. Lee WM. Acute liver failure. N Engl J Med 1993;329:1862-72.
22. Dupuy J, Fromemel D, Alagille D. Severe viral hepatitis type B in infancy. Lancet 1975;1:191-94.
23. CDC. Hepatitis Surveillance Report No. 54. Atlanta: Centers for Disease Control, 1992.
24. Karvountzis G, Redeker A, Peters R. Long-term follow-up studies of patients surviving fulminant viral hepatitis. Gastroenterology 1974;67:870-77.
25. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-68.
26. Kato Y, Nakao K, Hamasaki K et al. Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan. J Gastroenterol 2000;35:201-05.
27. de Franchis R, Meucci G, Vecchi M et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Int Med 1993;118:191-94.
28. Health and Vital Statistics, Republic of China (Taiwan), 1990-1999. Department of Health, Executive Yuan, Taiwan.
29. Tsai JF, Chang WY, Jeng JE et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993;41:296-300.
30. Bell BP, Sofair A, Manos MM et al. The epidemiology of newly-diagnosed chronic liver disease in the United States. Proceedings of the 11th International Symposium on Viral Hepatitis and Chronic Liver Disease, April 6-10, 2003, Sydney, Australia.
31. Frieden TR, Ozick L, McCord C et al. Chronic liver disease in central Harlem: The role of alcohol and viral hepatitis. Hepatology 1999;29: 883-88.
32. Neal JJ. The etiologic spectrum of chronic liver disease: Epidemiology and health impact of all causes of chronic hepatitis and cirrhosis. Thesis. Los Angeles, CA: University of California. Ann Arbor, MI: University Microfilms, 1992.
33. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. Lancet 1981;2:1129-33.
34. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Pub Health 1999;89:14-18.
35. Ding Z, Li R, Gong J et al. Epidemiological study on relationship between hepatitis B and liver cancer - a prospective study on development of liver cancer and distribution of HBsAg carriers and liver damage persons in Guangxi (Chinese). Chinese J Epidemiol (Chung-Hua Liu Hsing Ping Hsueh Tsa Chih) 1988;9:220-23.
36. Hall AJ and the Gambia Hepatitis Study Group. The Gambia hepatitis B control programme. In: Hollinger FB, Lemon SM, Margolis HS (eds). Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 1991, pp. 712-15.
37. The Gambia Hepatitis Intervention Study (GHIS) Annual report 1997.
38. Beasley RP. Hepatitis B virus: The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
39. Cancer Registry Annual Report, Republic of China (Taiwan), 1996. Department of Health, Executive Yuan, Taiwan 1999.
40. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Arch Intern Med 1990;150:1051-54.
41. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22.
42. Ryder RW, Whittle HC, Sanneh AB, Ajdukiewicz AB, Tulloch S, Yvonnet B. Persistent hepatitis B virus infection and hepatoma in The Gambia, west Africa. A case-control study of 140 adults and their 603 family contacts. Am J Epidemiol 1992;136:1122-31.
43. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400.
44. Tsai JF, Jeng JE, Ho MS et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996;73:1498-502.
45. Sun CA, Farzadegan H, You SL et al. Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: A population-based case-control study in Taiwan. Cancer Epidemiol Biomarkers Prev 1996;5: 173-78.
46. Inskip HM, Hall AJ, Chotard J, Loik F, Whittle H. Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: Factors influencing antibody response. Int J Epidemiol 1991;20:764-69.
47. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;34:168-74.
48. Centers for Disease Control. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb MortalWkly Rep 1991;40:1-25.
49. Anonymous. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000;355:561-65.
50. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87:14S-20S.
51. 2004 World Population Data Sheet. Population Reference Bureau, Washington, DC. 2004. Available at: www.prb.org/pdf04/ 04WorldDataSheet_Eng.pdf (Accessed July 21, 2005).
52. International Database. US Census Bureau 2004. http://www.census.gov (Accessed on October 5, 2005).
53. Yuen MF, Wong DKH, Sablon E et al. HBsAg seroclearance in chronic hepatitis B in the chinese: Virological, histological, and clinical aspects. Hepatology 2004;39:1694-701.
54. Hadziyannis SJ. Review: Hepatitis delta. J Gastroenterol Hepatol 1997;12:289-98.
55. Kirk GD, Lesi OA, Mendy M et al. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004;39:211-19.
56. Mele A, Tancredi F, Romano L et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 2001;184:905-08.
57. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999;179: 1319-25.
58. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Longterm response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatol 1999;29:954-59.
59. Liao SS, Li RC, Li H et al. Long-term efficacy of plasma-derived hepatitis B vaccine: A 15-year follow-up study among Chinese children. Vaccine 1999;17:2661-66.
60. Whittle H, Jaffar S, WansbroughMet al.Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002;325:569-73.
61. Lin HH, Wang LY, Hu CT et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: Sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003;69: 471-74.
62. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. J Hepatol 1999;29:924-27.
63. Coursaget P, Leboulleux D, Soumare M et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994;21:250-54.
64. McMahon BJ, Bruden DL, Petersen KM et al. Antibody levels and protection after hepatitis B vaccination: Results of a 15-year follow-up. Ann Int Med 2005;142:333-41.
65. Centers for Disease Control. Acute hepatitis B among children and adolescents - United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004;53:1015-18.
66. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 36:1855-59.
67. Fine PE. Herd immunity: History, theory, practice. Epidemiol Rev 1993;15:265-302.
68. Harpaz R, McMahon BJ, Margolis HS et al. Elimination of new chronic hepatitis B virus infections: Results of the Alaska immunization program. J Infect Dis 2000;181:413-18.